Previous Close | 167.89 |
Open | 168.59 |
Bid | 0.00 x 800 |
Ask | 170.45 x 800 |
Day's Range | 168.29 - 170.37 |
52 Week Range | 130.96 - 182.89 |
Volume | |
Avg. Volume | 5,623,520 |
Market Cap | 300.196B |
Beta (5Y Monthly) | 0.56 |
PE Ratio (TTM) | 62.56 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 6.20 (3.66%) |
Ex-Dividend Date | Apr 12, 2024 |
1y Target Est | N/A |
“We believe earnings growth is set for a healthier runway through 2024,” Morgan Stanley’s analysts wrote.
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Get a deeper insight into the potential performance of AbbVie (ABBV) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.